LPC
NERV icon

Lion Point Capital’s Minerva Neurosciences NERV Stock Holding History

Lion Point Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,000
Closed -$141K – 38
2025
Q4 		$141K Buy
+35,000
New +$130K 0.73% 36

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM

Lion Point Capital's NERV Position: Q1 2026 in Review

Lion Point Capital sold out of Minerva Neurosciences (NERV) in Q1 2026, closing a stake of 35,000 shares — an estimated $141K sold.

Lion Point Capital first reported a position in NERV in Q4 2025 and held it in 1 quarter. The position peaked at $141K in Q4 2025. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • Lion Point Capital reported no remaining Minerva Neurosciences position as of Q1 2026 after selling out during the quarter.
  • Lion Point Capital sold 35,000 Minerva Neurosciences shares in Q1 2026, an estimated $141K.
  • Lion Point Capital first reported a position in Minerva Neurosciences in Q4 2025 and held it in 1 quarter.
  • Lion Point Capital's Minerva Neurosciences position peaked at $141K in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.